Frankfurt - Delayed Quote EUR

Ono Pharmaceutical Co., Ltd. (ON4.F)

Compare
10.20
+0.30
+(3.03%)
At close: January 28 at 3:29:02 PM GMT+1
Currency in JPY All numbers in thousands
Download
Breakdown
TTM
3/31/2024
3/31/2023
3/31/2022
3/31/2021
Total Revenue
502,672,000.00
502,672,000.00
447,187,000.00
361,361,000.00
309,284,000.00
Cost of Revenue
127,126,000.00
127,126,000.00
110,062,000.00
93,511,000.00
85,573,000.00
Gross Profit
375,547,000.00
375,547,000.00
337,124,000.00
267,850,000.00
223,711,000.00
Operating Expense
215,611,000.00
215,611,000.00
195,161,000.00
164,654,000.00
125,381,000.00
Operating Income
159,936,000.00
159,936,000.00
141,963,000.00
103,196,000.00
98,330,000.00
Net Non Operating Interest Income Expense
3,798,000.00
3,798,000.00
1,565,000.00
1,836,000.00
2,556,000.00
Pretax Income
163,734,000.00
163,734,000.00
143,532,000.00
105,025,000.00
100,890,000.00
Tax Provision
35,694,000.00
35,694,000.00
30,619,000.00
24,340,000.00
25,392,000.00
Net Income Common Stockholders
127,977,000.00
127,977,000.00
112,723,000.00
80,519,000.00
75,425,000.00
Diluted NI Available to Com Stockholders
127,977,000.00
127,977,000.00
112,723,000.00
80,519,000.00
75,425,000.00
Basic EPS
266.61
266.61
230.85
162.19
151.11
Diluted EPS
266.57
266.57
230.79
162.16
151.09
Basic Average Shares
480,015.75
480,015.75
488,300.45
496,459.00
499,137.00
Diluted Average Shares
480,087.78
480,087.78
488,353.00
496,527.00
499,203.00
Total Operating Income as Reported
159,935,000.00
159,935,000.00
141,963,000.00
103,195,000.00
98,330,000.00
Total Expenses
342,737,000.00
342,737,000.00
305,223,000.00
258,165,000.00
210,954,000.00
Net Income from Continuing & Discontinued Operation
127,977,000.00
127,977,000.00
112,723,000.00
80,519,000.00
75,425,000.00
Normalized Income
127,977,000.00
127,977,000.00
112,723,000.00
80,519,000.00
75,425,000.00
Interest Income
4,027,000.00
4,027,000.00
2,478,000.00
2,710,000.00
2,693,000.00
Interest Expense
229,000.00
229,000.00
913,000.00
874,000.00
137,000.00
Net Interest Income
3,798,000.00
3,798,000.00
1,565,000.00
1,836,000.00
2,556,000.00
EBIT
163,963,000.00
163,963,000.00
144,445,000.00
105,899,000.00
101,027,000.00
EBITDA
182,103,000.00
182,103,000.00
161,896,000.00
123,620,000.00
116,847,000.00
Reconciled Cost of Revenue
127,126,000.00
127,126,000.00
110,062,000.00
93,511,000.00
85,573,000.00
Reconciled Depreciation
18,140,000.00
18,140,000.00
17,451,000.00
17,721,000.00
15,820,000.00
Net Income from Continuing Operation Net Minority Interest
127,977,000.00
127,977,000.00
112,723,000.00
80,519,000.00
75,425,000.00
Normalized EBITDA
182,103,000.00
182,103,000.00
161,896,000.00
123,620,000.00
116,847,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
3/31/2021 - 10/22/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

002422.SZ Sichuan Kelun Pharmaceutical Co., Ltd.
28.13
-0.04%
 
CVGU.F CSPC Pharmaceutical Group Limited
2.0000
+0.50%
 
600436.SS PIENTZEHUANG
202.51
+0.75%
 
4536.T Santen Pharmaceutical Co., Ltd.
1,553.50
-0.80%
 
CUP0.MU Chugai Pharmaceutical Co., Ltd.
19.90
-0.50%
 
4151.T Kyowa Kirin Co., Ltd.
2,317.00
-0.49%
 
4578.T Otsuka Holdings Co., Ltd.
8,125.00
+0.14%
 
600276.SS HENGRUI PHARMA
44.65
+0.02%
 
4568.T Daiichi Sankyo Company, Limited
4,399.00
-1.19%
 
ALPMY Astellas Pharma Inc.
9.87
+1.33%